Bone Biologics Corp (BBLG) financial statements (2020 and earlier)

Company profile

Business Address 2 BURLINGTON WOODS DRIVE,
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0001120
Cash and cash equivalents0001120
Prepaid expense0000000
Total current assets:0001120
Noncurrent Assets
Property, plant and equipment   0000
Total noncurrent assets:   0000
TOTAL ASSETS:0001120
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:0001000
Accounts payable0001000
Employee-related liabilities0000000
Other undisclosed accounts payable and accrued liabilities 0    0
Deferred compensation liability0000000
Due to related parties 1111109 1
Other undisclosed current liabilities0      
Total current liabilities:11211111011
Noncurrent Liabilities
Liabilities, other than long-term debt11    99
Due to related parties11    99
Total noncurrent liabilities:11    99
Total liabilities:12121111101010
Stockholders' equity
Stockholders' equity attributable to parent, including:(12)(11)(11)(10)(9)(7)(9)
Common stock0000000
Common stock, share subscribed but unissued, subscriptions receivable      (2)
Additional paid in capital55555555555551
Accumulated deficit(67)(67)(66)(65)(64)(62)(62)
Other undisclosed stockholders' equity attributable to parent      4
Total stockholders' equity:(12)(11)(11)(10)(9)(7)(9)
TOTAL LIABILITIES AND EQUITY:0001120

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues1,070      
Operating expenses(0)(0)(1)(1)(1)0(1)
Operating income (loss):(0)(0)(1)(1)(1)0(1)
Nonoperating expense(0)(0)  (0)(1) 
Interest and debt expense(0)(0)(0)(0) (0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    (0)0 
Loss from continuing operations before equity method investments, income taxes:(1)(1)(1)(1)(1)(0)(1)
Other undisclosed income from continuing operations before income taxes00  0  
Loss from continuing operations before income taxes:(1)(1)(1)(1)(1)(0)(1)
Income tax expense (benefit)0(0)(0) (0)(0)(0)
Net loss available to common stockholders, diluted:(1)(1)(1)(1)(1)(0)(1)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(1)(1)(1)(1)(1)(0)(1)
Comprehensive loss, net of tax, attributable to parent:(1)(1)(1)(1)(1)(0)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: